LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly

BACKGROUND: Oral octreotide capsules (OOC) are an approved treatment option in the United States for patients with acromegaly who have previously responded to injectable somatostatin receptor ligands (iSRLs). Safety and efficacy of OOC was demonstrated in the CHIASMA OPTIMAL trial (NCT03252353), sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Samson, Susan, Nachtigall, Lisa, Fleseriu, Maria, Molitch, Mark E, Giustina, Andrea, Haviv, Asi, Biermasz, Nienke, Kennedy, Laurence, Jensterle, Mojca, Manning, Patrick, Elenkova, Atanaska, Melmed, Shlomo, Strasburger, Christian J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627109/
http://dx.doi.org/10.1210/jendso/bvac150.984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627109/
http://dx.doi.org/10.1210/jendso/bvac150.984

Ejemplares similares